{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T09:15:52Z","timestamp":1776071752984,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ejpn.2019.05.002","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T14:02:37Z","timestamp":1557410557000},"page":"589-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Role of observational studies in supporting extrapolation of efficacy data from adults to children with epilepsy \u2014 A systematic review of the literature using lacosamide as an example"],"prefix":"10.1016","volume":"23","author":[{"given":"A.","family":"Arzimanoglou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Kalilani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Anamoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Golembesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Taeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bozorg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tofighy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wheless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2019.05.002_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nurt.2006.10.004","article-title":"Clinical development of antiepileptic drugs for children","volume":"4","author":"Garafalo","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejpn.2019.05.002_bib2","doi-asserted-by":"crossref","first-page":"e1242","DOI":"10.1542\/peds.2010-3487","article-title":"Extrapolation of adult data and other data in pediatric drug-development programs","volume":"128","author":"Dunne","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejpn.2019.05.002_bib3","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/epi.13859","article-title":"Extrapolating evidence of antiepileptic drug efficacy in adults to children \u22652 years of age with focal seizures: the case for disease similarity","volume":"58","author":"Pellock","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2019.05.002_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40272-018-0286-0","article-title":"A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation","volume":"20","author":"Arzimanoglou","year":"2018","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.ejpn.2019.05.002_bib5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s40263-016-0383-y","article-title":"Clinical drug development in epilepsy revisited: a proposal for a new paradigm streamlined using extrapolation","volume":"30","author":"Wadsworth","year":"2016","journal-title":"CNS Drugs"},{"issue":"Suppl. 9","key":"10.1016\/j.ejpn.2019.05.002_bib6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1528-1167.2005.00328.x","article-title":"Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs","volume":"46","author":"Bergey","year":"2005","journal-title":"Epilepsia"},{"issue":"Suppl. 9","key":"10.1016\/j.ejpn.2019.05.002_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1528-1167.2005.00324.x","article-title":"Practical management issues for idiopathic generalized epilepsies","volume":"46","author":"Benbadis","year":"2005","journal-title":"Epilepsia"},{"issue":"Suppl. 7","key":"10.1016\/j.ejpn.2019.05.002_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1528-1157.44.s7.6.x","article-title":"Clinical trials for treatment of primary generalized epilepsies","volume":"44","author":"Faught","year":"2003","journal-title":"Epilepsia"},{"issue":"Suppl. 9","key":"10.1016\/j.ejpn.2019.05.002_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1528-1167.2005.00327.x","article-title":"Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs","volume":"46","author":"Hitiris","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2019.05.002_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1046\/j.1528-1157.2003.26402.x","article-title":"EEG in adult-onset idiopathic generalized epilepsy","volume":"44","author":"Yenjun","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2019.05.002_bib11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1212\/WNL.37.6.993","article-title":"Concepts of absence epilepsies: discrete syndromes or biological continuum?","volume":"37","author":"Berkovic","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2019.05.002_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"110","author":"Rogawski","year":"2015","journal-title":"Epilepsy Res"},{"issue":"Suppl. 21","key":"10.1016\/j.ejpn.2019.05.002_bib13","first-page":"S287","article-title":"Efficacy and tolerability of adjunctive lacosamide in children and adolescents with uncontrolled focal seizures: a randomized, double-blind, placebo-controlled trial","volume":"82","author":"Farkas","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ejpn.2019.05.002_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejpn.2019.05.002_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"issue":"Suppl. 3","key":"10.1016\/j.ejpn.2019.05.002_bib16","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1542\/peds.2012-0055I","article-title":"Standard 6: age groups for pediatric trials","volume":"129","author":"Williams","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejpn.2019.05.002_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpn.2013.08.006","article-title":"Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy","volume":"18","author":"Grosso","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2019.05.002_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.pediatrneurol.2014.07.004","article-title":"Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy","volume":"51","author":"Pasha","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2019.05.002_bib19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.yebeh.2011.02.005","article-title":"Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy","volume":"20","author":"Gavatha","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2019.05.002_bib20","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00381-017-3586-8","article-title":"Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients","volume":"33","author":"Yildiz","year":"2017","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.ejpn.2019.05.002_bib21","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1684\/epd.2015.0782","article-title":"Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study","volume":"17","author":"Toupin","year":"2015","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.ejpn.2019.05.002_bib22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.braindev.2013.07.003","article-title":"Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy","volume":"36","author":"Kim","year":"2014","journal-title":"Brain Dev"},{"key":"10.1016\/j.ejpn.2019.05.002_bib23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.pediatrneurol.2010.12.003","article-title":"Experience with lacosamide in a series of children with drug-resistant focal epilepsy","volume":"44","author":"Guilhoto","year":"2011","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2019.05.002_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.sleep.2015.09.028","article-title":"Effective treatment of nocturnal frontal lobe epilepsy with lacosamide: a report of two cases","volume":"23","author":"Liguori","year":"2016","journal-title":"Sleep Med"},{"key":"10.1016\/j.ejpn.2019.05.002_bib25","first-page":"66","article-title":"Reversible inattention and hyperactivity in a child on lacosamide - in south Indian subpopulation","volume":"9","author":"Pasha","year":"2014","journal-title":"IOSR J Pharm Biol Sci"},{"key":"10.1016\/j.ejpn.2019.05.002_bib26","first-page":"119","article-title":"Effect of lacosamide on behaviour of children with refractory partial epilepsy","volume":"6","author":"Pasha","year":"2014","journal-title":"Int J Pharm Pharm Sci"},{"key":"10.1016\/j.ejpn.2019.05.002_bib27","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/epi.13466","article-title":"Lacosamide use in children with epilepsy: retention rate and effect of concomitant sodium channel blockers in a large cohort","volume":"57","author":"McGinnis","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2019.05.002_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.yebeh.2017.11.024","article-title":"The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting","volume":"79","author":"Sanmart\u00ed-Vilaplana","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2019.05.002_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11636260-000000000-00000","article-title":"Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicentre study in Spain","volume":"12","author":"Casas-Fern\u00e1ndez","year":"2012","journal-title":"Drugs R D"},{"key":"10.1016\/j.ejpn.2019.05.002_bib30","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/epi.14071","article-title":"Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies. A single-center observational study","volume":"59","author":"Rosati","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2019.05.002_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.seizure.2012.12.009","article-title":"Lacosamide in pediatric and adult patients: comparison of efficacy and safety","volume":"22","author":"Verrotti","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.ejpn.2019.05.002_bib32","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/0883073812436741","article-title":"Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study","volume":"27","author":"Rastogi","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2019.05.002_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejpn.2011.08.007","article-title":"Preliminary efficacy and safety of lacosamide in children with refractory epilepsy","volume":"16","author":"Heyman","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2019.05.002_bib34","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/jpc.12850","article-title":"Lacosamide as adjunctive therapy in treatment-resistant epilepsy in childhood","volume":"51","author":"Gulati","year":"2015","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.ejpn.2019.05.002_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/0883073812462887","article-title":"Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy","volume":"29","author":"Yorns","year":"2014","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2019.05.002_bib36","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0883073816630084","article-title":"Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy","volume":"31","author":"Miskin","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2019.05.002_bib37","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ane.12221","article-title":"Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome","volume":"129","author":"Grosso","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ejpn.2019.05.002_bib38","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/ane.12251","article-title":"Should be prescribed lacosamide in patients with Lennox-Gastaut syndrome?","volume":"130","author":"Andrade-Machado","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ejpn.2019.05.002_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/WNF.0b013e318255b649","article-title":"Lacosamide in Lennox-Gastaut syndrome: case report","volume":"35","author":"Andrade-Machado","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ejpn.2019.05.002_bib40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.seizure.2011.12.010","article-title":"Lacosamide treatment of juvenile myoclonic epilepsy","volume":"21","author":"Afra","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.ejpn.2019.05.002_bib41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.yebeh.2011.10.023","article-title":"Lacosamide use in refractory idiopathic primary generalized epilepsy","volume":"23","author":"Zangaladze","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2019.05.002_bib42","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.eplepsyres.2014.08.021","article-title":"Lacosamide efficacy in epileptic syndromes with continuous spike and waves during slow sleep (CSWS)","volume":"108","author":"Grosso","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ejpn.2019.05.002_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2016.12.015","article-title":"Lacosamide for uncontrolled primary generalized tonic-clonic seizures: an open-label pilot study with 59-week extension","volume":"130","author":"Wechsler","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ejpn.2019.05.002_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ebcr.2017.08.001","article-title":"Lacosamide for refractory generalized tonic-clonic seizures of non-focal origin in clinical practice: a clinical and VEEG study","volume":"8","author":"Abarrategui","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"issue":"Suppl. 1","key":"10.1016\/j.ejpn.2019.05.002_bib45","first-page":"159","article-title":"Role of lacosamide as adjunctive treatment of adults with primary generalized epilepsy","volume":"11","author":"Afra","year":"2011","journal-title":"Epilepsy Curr"},{"issue":"Suppl. 1","key":"10.1016\/j.ejpn.2019.05.002_bib46","first-page":"206","article-title":"Adjunctive treatment with Lacosamide: an option for generalized epilepsy?","volume":"11","author":"Arnold","year":"2011","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.ejpn.2019.05.002_bib47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ebcr.2016.09.006","article-title":"Unmasking of myoclonus by lacosamide in generalized epilepsy","volume":"7","author":"Birnbaum","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"issue":"14 Suppl","key":"10.1016\/j.ejpn.2019.05.002_bib48","article-title":"A case report of exacerbation of myoclonus in idiopathic generalized epilepsy from use of lacosamide","volume":"84","author":"Swaminathan","year":"2015","journal-title":"Neurology"},{"issue":"Suppl. 1","key":"10.1016\/j.ejpn.2019.05.002_bib49","article-title":"Lacosamide in progressive myoclonic epilepsy type 1: a case report","volume":"11","author":"Polovitz","year":"2011","journal-title":"Epilepsy Curr"},{"issue":"10 Suppl","key":"10.1016\/j.ejpn.2019.05.002_bib50","article-title":"Lacosamide experience in patients with Lennox-Gastaut Syndrome and epilepsy","volume":"82","author":"Bermejo","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2019.05.002_bib51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.seizure.2015.10.009","article-title":"Efficacy and tolerability of add-on Lacosamide treatment in adults with Lennox-Gastaut syndrome: an observational study","volume":"33","author":"Andrade-Machado","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.ejpn.2019.05.002_bib52","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.yebeh.2010.09.024","article-title":"Does lacosamide aggravate Lennox-Gastaut syndrome? Report on three consecutive cases","volume":"19","author":"Cuzzola","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejpn.2019.05.002_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ebcr.2018.01.001","article-title":"Lacosamide-induced excessive laughing in a patient with Lennox\u2013Gastaut syndrome","volume":"10","author":"Algahtani","year":"2018","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.ejpn.2019.05.002_bib54","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2019.05.002_bib55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2019.05.002_bib56","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2019.05.002_bib57","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","article-title":"Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology","volume":"8","author":"Arzimanoglou","year":"2009","journal-title":"Lancet Neurol"},{"issue":"Suppl. 4","key":"10.1016\/j.ejpn.2019.05.002_bib58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/epi.12732","article-title":"The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome","volume":"55","author":"Montouris","year":"2014","journal-title":"Epilepsia"},{"issue":"Suppl. 8","key":"10.1016\/j.ejpn.2019.05.002_bib59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1528-1167.2009.02233.x","article-title":"Some treatments cause seizure aggravation in idiopathic epilepsies (especially absence epilepsy)","volume":"50","author":"Somerville","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl. 9","key":"10.1016\/j.ejpn.2019.05.002_bib60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1528-1167.2005.00325.x","article-title":"Seizure aggravation in idiopathic generalized epilepsies","volume":"46","author":"Chaves","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2019.05.002_bib61","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1017\/S0012162206000843","article-title":"Aggravation of epilepsy by anti-epileptic drugs","volume":"48","author":"Gayatri","year":"2006","journal-title":"Dev Med Child Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejpn.2019.05.002_bib62","first-page":"S2","article-title":"Psychiatric and behavioural disorders in children with epilepsy (ILAE task force report): epidemiology of psychiatric\/behavioural disorder in children with epilepsy","volume":"18","author":"Sillanp\u00e4\u00e4","year":"2016","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.ejpn.2019.05.002_bib63","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1017\/S1047951114001188","article-title":"Lacosamide-induced atrial tachycardia in a child with hypoplastic left-heart syndrome: importance of assessing additional proarrhythmic risks","volume":"25","author":"Loomba","year":"2015","journal-title":"Cardiol Young"},{"key":"10.1016\/j.ejpn.2019.05.002_bib64","author":"UCB Pharma"},{"key":"10.1016\/j.ejpn.2019.05.002_bib65","author":"UCB Inc"},{"key":"10.1016\/j.ejpn.2019.05.002_bib66","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.yebeh.2012.01.014","article-title":"What is the right dose of lacosamide in pediatric patients with intractable epilepsy?","volume":"23","author":"Vishwanath","year":"2012","journal-title":"Epilepsy Behav"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379819300388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379819300388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:35:47Z","timestamp":1761071747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379819300388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1090379819300388"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2019.05.002","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of observational studies in supporting extrapolation of efficacy data from adults to children with epilepsy \u2014 A systematic review of the literature using lacosamide as an example","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2019.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}